Valued at a market cap of $102.4 billion, HCA Healthcare, Inc. (HCA) owns and operates hospitals and associated healthcare entities. The Nashville, Tennessee-based firm operates normal and acute care hospitals, outpatient healthcare amenities, and behavioral hospitals, which give therapeutic packages comprising youngster, adolescent, and grownup psychiatric care, adolescent and grownup alcohol and drug abuse remedy, and counseling providers. It is scheduled to announce its fiscal Q3 earnings for 2025 earlier than the market opens on Friday, Oct. 24.
Forward of this occasion, analysts anticipate this healthcare firm to report a revenue of $5.64 per share, up 11.7% from $5.05 per share within the year-ago quarter. The corporate has a promising trajectory of persistently beating Wall Avenue’s bottom-line estimates in every of the final 4 quarters. In Q2, HCA’s EPS of $6.84 exceeded the forecasted determine by a notable margin of 10.5%.
For fiscal 2025, analysts anticipate HCA to report a revenue of $26.30 per share, representing a 19.8% enhance from $21.96 per share in fiscal 2024. Moreover, its EPS is predicted to develop 6.2% year-over-year to $27.94 in fiscal 2026.
HCA has lagged behind the S&P 500 Index’s ($SPX) 17.9% return over the previous 52 weeks, with its shares up 14.4% over the identical time-frame. Nevertheless, it has outpaced the Well being Care Choose Sector SPDR Fund’s (XLV) 4.5% loss over the identical time interval.
On Jul. 25, shares of HCA tumbled 2.1% after reporting its Q2 outcomes. The corporate’s income improved 6.4% 12 months over 12 months to $18.6 billion, whereas its adjusted EPS of $6.84 grew 24.4% from the identical interval final 12 months and got here in 10.5% forward of analyst estimates. Nevertheless, its same-facility inpatient and outpatient surgical procedure instances declined in comparison with the prior-year quarter, which could have made buyers jittery.
Wall Avenue analysts are reasonably optimistic about HCA’s inventory, with a “Reasonable Purchase” ranking total. Amongst 26 analysts masking the inventory, 13 advocate “Sturdy Purchase,” two point out “Reasonable Purchase,” and 11 counsel “Maintain.” Whereas the corporate is buying and selling above its imply value goal of $409.77, its Avenue-high value goal of $449 implies a 2.6% potential upside from the present ranges.
On the date of publication, Neharika Jain didn’t have (both instantly or not directly) positions in any of the securities talked about on this article. All info and knowledge on this article is solely for informational functions. This text was initially printed on Barchart.com